Navigation Links
Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
Date:2/9/2010

PARIS, Feb. 9 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc. ( CHTT).  

The tender offer and withdrawal rights expired at 12:00 midnight, New York City time, on February 8, 2010.  The depositary for the tender offer has advised sanofi-aventis that, as of the expiration time, approximately 18,611,072 shares of Chattem common stock (including approximately 2,853,283 shares subject to guarantees of delivery) were validly tendered and not withdrawn representing approximately 89.8% of the shares on a fully-diluted basis (as defined in the merger agreement).  All shares that were validly tendered and not validly withdrawn have been accepted for purchase, and payment for such shares will be made promptly in accordance with the terms of the tender offer at the offer price of $93.50 per share, net to the seller in cash, without interest and less any required withholding taxes.  

Sanofi-aventis intends to effect a "short-form" merger under Tennessee law after exercising its top-up option under the merger agreement, and Chattem will become an indirect, wholly-owned subsidiary of sanofi-aventis.  As a result of the merger, any shares of Chattem common stock not tendered in the tender offer will be cancelled and (except for shares held by sanofi-aventis, Chattem and their subsidiaries) converted into the right to receive the same $93.50 per share in cash paid in the tender offer.

The transaction is a significant milestone in sanofi-aventis' transformational strategy.  By strengthening its presence in the U.S. consumer healthcare market, which represents 25 percent of the current worldwide opportunity, sanofi-aventis is further securing its position as a global, integrated healthcare company and building a significant platform for future growth.

The Depositary and Paying Agent for the tender offer is Computershare Trust Company, N.A., c/o Voluntary Corporate Actions, P.O. Box 43011, Providence, RI 02940-3011.  The Dealer Manager for the tender offer is Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004.  The Information Agent for the tender offer is MacKenzie Partners, Inc., 105 Madison Avenue, New York, NY 10016.  The tender offer materials may be obtained at no charge by directing a request by mail to MacKenzie Partners, Inc. or by calling toll-free at (800) 322-2885.

Forward Looking Statements

This press release contains forward-looking statements.  Forward-looking statements are statements that are not historical facts.  These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions.  Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008.  Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Important Additional Information

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of Chattem. The tender offer is being made pursuant to a Tender Offer Statement on Schedule TO, containing an offer to purchase, form of letter of transmittal and related tender offer documents, filed by River Acquisition Corp. and sanofi-aventis with the U.S. Securities and Exchange Commission (the "SEC") on January 11, 2010.   Chattem filed a Solicitation/Recommendation Statement on Schedule 14D-9 relating to the tender offer with the SEC on January 11, 2010.  Sanofi-aventis and Chattem have mailed these documents to all Chattem shareholders of record.  These documents, as they may be amended from time to time, contain important information about the tender offer and Chattem shareholders are urged to read them carefully before any decision is made with respect to the tender offer.  The tender offer materials may be obtained at no charge by directing a request by mail to MacKenzie Partners, Inc., 105 Madison Avenue, New York, New York 10016, or by calling toll-free at (800) 322-2885, and may also be obtained at no charge at the website maintained by the SEC at www.sec.gov.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.  Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com.

SOURCE Sanofi-aventis

RELATED LINKS
http://www.sanofi-aventis.com

'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
2. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
3. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
4. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
5. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
6. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
7. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
8. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
9. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
10. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
11. Sanofi-aventis Stands Behind the Safety of Lantus(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 FinancialBuzz.com News Commentary  ... According ... of cannabis market research, the legal cannabis market is projected ... 2021, despite conflicting signals from the current presidential administration. The ... the two biggest drivers of growth in this industry are ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... in Drug Discovery and Diagnostics, 2017 - 2035" report to ... The ... current landscape and future outlook of the growing market of deep ... data revolution, deep learning algorithms have emerged as a novel solution ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Appliances and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), ... Sunshine Heart Inc. (NASDAQ: SSH ). These companies ... of its prior gains on Thursday, March 23 rd , ... the afternoon, while shares of health care companies in the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless ... interrelate. “End Time GPS” is the creation of published author, Wesley Gerboth, a ... on military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center PA ... Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite 440, ... newest location will provide patients living in the north Houston area (The Woodlands, Conroe, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
Breaking Medicine News(10 mins):